Skip to content

Study · Non-randomized trial · n = 112 · 2010

3 results

Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.

Hosseini MA, Aleyasin A, Saeedi H, Mahdavi A

The journal of obstetrics and gynaecology research1 Jun 2010Cited by 27 (Europe PMC)

PMID20598044 (opens in a new tab)DOI10.1111/j.1447-0756.2010.01247.x (opens in a new tab)PepBankPUB-20598044
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In infertile PCOS patients, cetrorelix produced significantly more retrieved oocytes than buserelin.

    In plain wordsIn infertile PCOS patients, cetrorelix produced more retrieved oocytes than buserelin.

    Peptide
    Cetrorelix
    Outcome
    IncreaseRetrieved oocytes
    Study

    n = 112

    Comparator
    Buserelin protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Regarding chemical and clinical pregnancy rates, the number of retrieved oocytes was significantly higher and OHSS was significantly lower in the antagonist group.
    1 context sentence
    Summary · context
    The present clinical trial compared GnRH antagonist (cetrorelix) and GnRH agonist (buserelin) protocols during COH of 112 infertile PCOS patients entering assisted reproduction cycles.
  2. 02HumanNon-randomized trialSafety outcome

    In infertile PCOS patients, OHSS was significantly lower with cetrorelix than with buserelin.

    In plain wordsIn infertile PCOS patients, ovarian hyperstimulation syndrome was less frequent with cetrorelix than with buserelin.

    Peptide
    Cetrorelix
    Outcome
    DecreaseOHSS incidence
    Study

    n = 112

    Comparator
    Buserelin protocol
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Regarding chemical and clinical pregnancy rates, the number of retrieved oocytes was significantly higher and OHSS was significantly lower in the antagonist group.
    1 context sentence
    Summary · context
    The present clinical trial compared GnRH antagonist (cetrorelix) and GnRH agonist (buserelin) protocols during COH of 112 infertile PCOS patients entering assisted reproduction cycles.
  3. 03HumanNon-randomized trialEfficacy outcome

    In infertile PCOS patients, FSH, LH, follicle numbers, mature oocyte frequency, gonadotropin injections, hCG day, estradiol and abortion were similar between cetrorelix and buserelin.

    In plain wordsIn infertile PCOS patients, hormone levels, follicle counts, egg maturity, gonadotropin use, hCG day, estradiol and abortion were similar with cetrorelix and buserelin.

    Peptide
    Cetrorelix
    Outcome
    No significant changeFSH, LH, follicles, mature oocytes, gonadotropin use, hCG day, estradiol and abortion
    Study

    n = 112

    Comparator
    Buserelin protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Follicle stimulating hormone (FSH), luteinizing hormone (LH) levels, number of follicles, number of follicles >18 mm, relative frequency of mature oocytes, number and days of gonadotropin injections, day of human chorionic gonadotropin (HCG) administration,
    Summary
    estradiol level and abortion were similar between the two groups.
    1 context sentence
    Summary · context
    The present clinical trial compared GnRH antagonist (cetrorelix) and GnRH agonist (buserelin) protocols during COH of 112 infertile PCOS patients entering assisted reproduction cycles.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.